BioLayer assays Prince of Wales
Wednesday, 10 September, 2008
BioLayer Corporation [ASX: BLS] has officially entered into a commercial agreement with the Prince of Wales Medical Research Institute.
The two organisations plan to collaborate on an assay and other diagnostic tools for use in the early detection of neurodegenerative diseases such as Parkinson's.
The companies will share IP to create the new detection tools. Under the agreement, BioLayer has the option to develop existing IP from the Prince of Wales under license.
BioLayer expects to exercise that option early next year.
BioLayer has also filed a patent application for a new approach to protecting assay processes for the early detection of neurodegenerative diseases.
The last mile of life sciences innovation
How do we translate technological possibility into meaningful real-world impact?
Machine learning uncovers patterns in DNA methylation
A new machine-learning method identifies differentially methylated DNA regions without sample...
HRT linked to lower dementia risk in some women
Hormone replacement therapy may reduce the risk of dementia — particularly for certain...
